Total Payments
$80,756
2023 Payments
$5,725
Companies
13
Transactions
98
Payment Breakdown by Category
Consulting$54,186 (67.1%)
Other$8,967 (11.1%)
Travel$8,247 (10.2%)
Research$7,555 (9.4%)
Food & Beverage$1,686 (2.1%)
Education$114.67 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $54,186 | 20 | 67.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,967 | 3 | 11.1% |
| Travel and Lodging | $8,247 | 32 | 10.2% |
| Unspecified | $7,555 | 11 | 9.4% |
| Food and Beverage | $1,686 | 29 | 2.1% |
| Education | $114.67 | 3 | 0.1% |
Payments by Type
General
$73,200
87 transactions
Research
$7,555
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $27,634 | 30 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $17,913 | 28 | $0 (2021) |
| Janssen Research & Development, LLC | $9,256 | 3 | $0 (2020) |
| Avanir Pharmaceuticals, Inc. | $6,417 | 9 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $5,428 | 15 | $0 (2020) |
| Mitsubishi Tanabe Pharma Development America, Inc. | $4,500 | 2 | $0 (2019) |
| Novo Nordisk AS | $3,200 | 3 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,225 | 1 | $0 (2023) |
| ITI, Inc. | $2,000 | 1 | $0 (2020) |
| Neurocrine Biosciences, Inc. | $2,000 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $5,725 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($2,225) |
| 2021 | $3,200 | 2 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($3,200) |
| 2020 | $12,789 | 5 | Janssen Research & Development, LLC ($8,075) |
| 2019 | $22,949 | 40 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($8,476) |
| 2018 | $22,459 | 28 | Shire North American Group Inc ($20,459) |
| 2017 | $13,633 | 19 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($5,253) |
All Payment Transactions
98 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2023 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 12/01/2023 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $375.00 | General |
| 08/17/2023 | Neurocrine Biosciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 06/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,225.00 | General |
| 08/23/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 05/07/2021 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 11/09/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $984.00 | General |
| 08/06/2020 | ITI, Inc. | CAPLYTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PSYCHIATRY | ||||||
| 05/05/2020 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 02/28/2020 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $8,075.00 | General |
| 02/13/2020 | Sunovion Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $29.61 | General |
| 11/15/2019 | Janssen Research & Development, LLC | SPRAVATO (Drug) | Travel and Lodging | In-kind items and services | $1,055.80 | General |
| Category: Neuroscience | ||||||
| 11/15/2019 | Janssen Research & Development, LLC | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Neuroscience | ||||||
| 10/05/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $201.71 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | ||||||
| 10/05/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $121.99 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | ||||||
| 10/05/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $50.00 | Research |
| Study: Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | ||||||
| 10/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $201.71 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/04/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $650.30 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $128.75 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 10/03/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | — | In-kind items and services | $124.99 | Research |
| Study: A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | ||||||
| 08/16/2019 | Allergan Inc. | VRAYLAR (Drug) | Education | In-kind items and services | $35.00 | General |
| Category: NEUROSCIENCE | ||||||
| 07/10/2019 | Sunovion Pharmaceuticals Inc. | DASOTRALINE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,107.00 | General |
| Category: CNS | ||||||
| 06/07/2019 | Shire North American Group Inc | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE- AND PLACEBO-CONTROLLED TRIAL OF THE SAFETY AND EFFICACY OF OPC-64005 IN THE TREATMENT OF ADULT ATTENTION-DEFICITHYPERACTIVITY DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $5,976 | 2 |
| A PHASE IIIB MULTI-CENTER, OPEN-LABEL, MIRROR-IMAGE, STUDY IN ADULT SUBJECTS WITH SCHIZOPHRENIA TREATED PROSPECTIVELY FOR 6-MONTHS WITH ABILIFY MYCITE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $1,206 | 6 |
| Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD | Otsuka Pharmaceutical Development & Commercialization, Inc. | $373.70 | 3 |
About Dr. Susan Mcelroy, MD
Dr. Susan Mcelroy, MD is a Psychiatry healthcare provider based in Mason, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841385986.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Susan Mcelroy, MD has received a total of $80,756 in payments from pharmaceutical and medical device companies, with $5,725 received in 2023. These payments were reported across 98 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($54,186).
Ad
Practice Information
- Specialty Psychiatry
- Location Mason, OH
- Active Since 10/04/2006
- Last Updated 08/25/2008
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1841385986
Products in Payments
- DASOTRALINE (Drug) $5,302
- ABILIFY MAINTENA (Drug) $4,297
- CAPLYTA (Drug) $2,000
- SPRAVATO (Drug) $1,181
- ABILIFY TABLET (Drug) $889.32
- VRAYLAR (Drug) $108.96
- BEVESPI AEROSPHERE (Drug) $41.22
- Victoza (Drug) $32.27
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Mason
Dr. Danielle Johnson, Md, MD
Psychiatry — Payments: $17,762
Psychiatry $17,762
Joshua Nnanji, Md, MD
Psychiatry — Payments: $6,100
Psychiatry $6,100
David Picone, D.o, D.O
Psychiatry — Payments: $2,877
Psychiatry $2,877
Hasan Bakhtier, M.d, M.D
Psychiatry — Payments: $2,208
Psychiatry $2,208
Nelson Rodriguez, Md, MD
Psychiatry — Payments: $1,847
Psychiatry $1,847
Dr. Saba Chughtai, M.d, M.D
Psychiatry — Payments: $1,382
Psychiatry $1,382